EQUITY - SECTOR / INDUSTRY FOCUS Series 2020-2, ADT 2019

Health Care Opportunities Portfolio // Portfolio Selected by: Peroni Portfolio Advisors, Inc.

Morningstar Equity Style BoxTM Investment Objective & Strategy

The Health Care Opportunities Portfolio, a unit investment trust (UIT), seeks to provide capital appreciation by investing in a portfolio of common stocks of companies involved in various areas of the health care sector including biotechnology, life sciences, medical equipment/technology, health care providers and pharmaceuticals. The portfolio was selected by Eugene E. Peroni, Jr. of Peroni Portfolio Advisors, Inc., the Portfolio Consultant, through the application of his proprietary method of technical analysis, the Peroni Method®, with consideration of investment opportunities under the health care theme. Ticketing Information CUSIP (Cash/Reinvest) 00780M743 / 750 Health Care Today Fee-Based CUSIP (Cash/Reinvest) 00780M768 / 776 MSWM Cash AHCP202 The United States Census Bureau projects a rapid increase in the elderly population over the next several decades and beyond. Baby boomers are the single largest generation in American history Essential Information and this generation may require massive amounts of health care in the near future. Globally, Unit price at inception (per unit) $10.000 people are living longer than they used to due to advances in health care technology, treatments Initial redemption price (per unit) $9.7750 and services. In this regard, the Health Care Opportunities Portfolio includes stocks in a number of Initial date of deposit 6/11/2020 industries involved in the many facets of health care that should be considered long term when Portfolio ending date 6/8/2022 investing in this diverse sector. Distribution frequency Semi-Annual, if any Number of Holdings 45 Historical 12-Month Distribution Rate of Trust Holdings* 0.33% *The distribution rate paid by the trust may be higher or lower than the amount shown above due to factors including, but not limited to, changes in the price of trust units, changes (including reductions) in distributions paid by issuers, changes in actual trust expenses and sales of securities in the portfolio. There is no guarantee that the issuers of the securities included in the trust will pay any distributions in the future. The Historical 12-Month Distribution Rate of Trust Holdings is calculated by taking the weighted average of the regular income distributions paid by the securities included in the trust’s portfolio over the 12 months preceding the trust’s date of deposit reduced to account for the effects of trust fees and expenses. The percentage shown is based on a $10 unit price. This historical rate is for illustrative purposes only and is not indicative of amounts that will actually be distributed by the trust.

Sales Charges (Based on $10 unit price)+ As a % of $10 Amount per Standard Accounts unit price 100 units Initial sales fee 0.00% $0.00 Deferred sales fee 2.25% $22.50 Creation & Development fee 0.50% $5.00 Maximum sales fee 2.75% $27.50

As a % of $10 Amount per Fee-Based Accounts unit price 100 units Maximum sales fee 0.50% $5.00 +The initial sales fee is the difference between the total sales fee (maximum of 2.75% of the unit offering price) and the sum of the remaining deferred sales fee and the total creation and development fee. The deferred sales fee is fixed at $0.225 per unit and is paid in three monthly installments beginning December 20, 2020. The creation and development fee is fixed at $0.05 per unit and is paid at the end of the initial offering period (anticipated to be approximately three months). When the public offering price per unit is less than or equal to $10, you will not pay an initial sales fee. When the public offering price per unit price is greater than $10 per unit, you will pay an initial sales fee. The initial and deferred sales fees may not apply Page 1 of 4 to fee-based accounts. See the prospectus for more details about fee-based account eligibility requirements. Advisors Asset Management, Inc. (AAM) is a SEC registered investment advisor and member FINRA/SIPC. Health Care Opportunities Portfolio Series 2020-2, ADT 2019

Portfolio Holdings (as of date of deposit)

Ticker Market Value Ticker Market Value Symbol Issue Name Per Share* Symbol Issue Name Per Share* Health Care (100%) Health Care (continued...) Health Care Equipment & Services (46.76%) Pharmaceuticals, Biotechnology (53.24%) ABMD ABIOMED, Inc. $250.85 ABBV AbbVie, Inc. $96.90 ABT Abbott Laboratories 92.16 AMGN Amgen, Inc. 227.12 CHE Chemed Corporation 448.70 ARNA Arena Pharmaceuticals, Inc. 64.60 COO The Cooper Companies, Inc. 298.63 AZN AstraZeneca PLC 53.64 DGX Quest Diagnostics, Inc. 114.31 BHVN Biohaven Pharmaceutical Holding Company Ltd. 66.67 DHR Danaher Corporation 172.69 BMRN BioMarin Pharmaceutical, Inc. 107.66 DVA DaVita, Inc. 82.90 BMY Bristol-Myers Squibb Company 60.16 DXCM DexCom, Inc. 385.17 CRL Charles River Laboratories International, Inc. 181.71 EW Edwards Lifesciences Corporation 73.28 ICLR ICON PLC 165.58 HUM Humana, Inc. 392.51 ILMN Illumina, Inc. 359.05 IDXX IDEXX Laboratories, Inc. 321.89 INCY Incyte Corporation 93.04 ISRG Intuitive Surgical, Inc. 585.38 JNJ Johnson & Johnson 147.80 LH Laboratory Corporation of America Holdings 175.10 LGND Ligand Pharmaceuticals, Inc. 117.58 MASI Masimo Corporation 225.69 LLY Eli Lilly and Company 151.00 MOH Molina Healthcare, Inc. 178.84 MRK Merck & Company, Inc. 81.77 QDEL Quidel Corporation 166.76 MTD Mettler-Toledo International, Inc. 812.61 RMD ResMed, Inc. 166.50 NBIX Neurocrine Biosciences, Inc. 118.34 STE STERIS PLC 159.64 REGN Regeneron Pharmaceuticals, Inc. 606.59 TFX Teleflex, Inc. 366.73 RGEN Repligen Corporation 120.01 UNH UnitedHealth Group, Inc. 305.75 SGEN Seattle Genetics, Inc. 156.70 WST West Pharmaceutical Services, Inc. 212.87 SRPT Sarepta Therapeutics, Inc. 159.83 TECH Bio-Techne Corporation 262.00 TMO Thermo Fisher Scientific, Inc. 352.80 VRTX Vertex Pharmaceuticals, Inc. 274.34 *As of 6/10/2020 and may vary thereafter.

Sector/Industry Group Breakdown** Holdings Style Summary** Country of Organization**

% of Portfolio % of Portfolio % of Portfolio Health Care 100.00% Large-Cap Growth 20.08% United States 91.16% Health Care Equipment & Services 46.76% Large-Cap Value 6.59% Ireland 4.41% Pharmaceuticals, Biotechnology 53.24% Large-Cap Blend 20.15% United Kingdom 2.23%

Source: Global Industry Classification Standard (GICS) Mid-Cap Growth 37.68% British Virgin Islands 2.20% Mid-Cap Value 4.44% **As of 6/11/2020 and may vary thereafter. Breakdowns are Source: Bloomberg based on the sources shown and may differ from any Mid-Cap Blend 4.47% category definitions used in selecting the trust portfolio. Small-Cap Growth 6.59%

Source: Morningstar

Page 2 of 4

Intelligent Investments. Independent Ideas. Health Care Opportunities Portfolio Series 2020-2, ADT 2019

The Peroni Method®

The Peroni Method® is a proprietary form of technical analysis used by Eugene E. Peroni, Jr. of Peroni Portfolio Advisors, Inc. which uses a bottom-up approach in selecting stocks for certain AAM sector unit investment trusts. The foundation of this methodology is the basic understanding that every stock has its own “fingerprint” in the market place. Mr. Peroni tracks hundreds of stocks on a daily basis, identifying leading stocks and sectors in the market by analyzing price movements, money flow trends, and relative strength characteristics. His studies include the examination of a stock’s price architecture using hand-drawn point and figure charts which have been part of the methodology for over half a century.

This hands-on research approach may be an attractive investment alternative to traditional fundamental analysis in that it considers a stock’s individual technical merits along with economic, monetary and geopolitical factors. The Peroni Method® may uncover emerging trends that could correspond to future stock performance. It has endured volatile markets while providing investors with uncommon insights and unique investment opportunities.

Key Points to Consider

• The speed and scale of the R&D response to the COVID-19 outbreak is unprecedented in human history, with billions of dollars being spent and committed in pursuit of drugs, vaccines and diagnostics for the virus. The expert consensus is that enhanced treatments for COVID-19 will likely be available by the end of 2020; and only 12 to 18 months will likely be needed to bring a vaccine to market at sufficient scale for widespread immunization, compared with the typical five or more years.1

• Chronic diseases and conditions are on the rise worldwide. An ageing population and changes in societal behavior are contributing to a steady increase in common and costly long-term health problems. The middle class is growing; and with urbanization accelerating, people are adopting a more sedentary lifestyle. This is pushing obesity rates and cases of diseases such as diabetes upward. According to the World Health Organization, chronic disease prevalence is expected to rise 57% between 2017 and 2020, causing increased demand on healthcare systems worldwide.2

• Recent health care statistics show that it is one of the largest and the fastest-growing industries in the world.3 • Global health care spending could reach over $10 trillion by 2022. • U.S. health care expenditures are expected to reach $4.3 trillion by 2023. • The U.S. has the greatest health care spending, sitting at $10,224 per capita.

• According to the National Health Expenditure Data, under current U.S. law, national health spending is projected to grow at an average rate of 5.5% per year for 2018-27 and estimated to reach nearly $6.0 trillion by 2027. U.S. healthcare spending is projected to grow 0.8 percentage points faster than Gross Domestic Product (GDP) per year over the 2018-27 period; as a result, the health share of GDP and is expected to rise from 17.9% in 2017 to 19.4% by 2027. Also, prices for health care goods and services are projected to grow somewhat faster over 2018-27 (2.5% compared to 1.1% for 2014-17).4

• Every day 10,000 baby boomers in the United States turn 65 and it is no secret that the nation’s already-strained health-care system is trying to keep longer- living seniors out of hospitals, assisted-living facilities and nursing homes and, instead, in their own homes. According to the Centers for Medicare & Medicaid Services, the U.S. spent an estimated $103 billion on home health care last year, a number predicted to reach at least $173 billion by 2026. At the 2019 Consumer Electronics Show in Las Vegas, there were 25% more health-related exhibitors than in 2018, reflecting that leveraging new technology may be another way to address the in-home care dilemma. The global smart home health-care market is predicted to reach $30 billion by 2023, up from $4.5 billion in 2017, according to Research & Markets.5

• The global population of 7.7 billion will increase to 9.7 billion by midcentury and may peak at 10.9 billion by around 2100, the United Nations said. People 65 or older were the fastest-growing segments of the global population and by 2050, the projection said, one in six people will be older than 65, up from one in 11 in 2019. Also, the number of people aged 80 or older, is expected to triple from 143 million presently to 426 million by 2050.6

1 McKinsey & Company, COVID-19: Implications for Business, 6/4/2020 2 PwC.com, Chronic diseases and conditions are on the rise, © 2017 - 2020 PwC 3 PolicyAdvice, The State of Health Care Industry (2020), 12/5/2019 4 CMS.gov, Research, Statistics, Data & Systems, NHE Fact Sheet, 12/5/2019 5 CNBC.com, America’s $103 billion home healthcare system is in a crisis as worker shortage worsens, 4/9/2019 6 The New York Times, The Globe is Going Gray Fast U.N. Says in New Forecast, 6/17/2019

Page 3 of 4

Intelligent Investments. Independent Ideas. Health Care Opportunities Portfolio Series 2020-2, ADT 2019

Gene Peroni - In The Media

Gene has appeared on CNBC, Bloomberg Radio, CBS News Radio, Fox Business Network, MarketWatch, Nightly Business Report and Wall Street Journal Radio. He has been quoted in publications such as The Wall Street Journal, The New York Times, U.S. News and World Report, Investors Business Daily and Forbes. In addition, Gene produces a daily stock market commentary available in a concise, easily accessible podcast.

Unit Investment Trusts (UITs) are sold only by prospectus. You should consider the trust’s investment objectives, risks, charges and expenses carefully before investing. Contact your financial professional or visit Advisors Asset Management online at www.aamlive.com/uit to obtain a prospectus, which contains this and other information about the trust. Read it carefully before you invest.

Risks and Considerations: Unit values will fluctuate with the portfolio of underlying securities and may be worth more or less than the original purchase price at the time of redemption. There is no guarantee that the objective of the portfolio will be achieved. Additionally, the trust may terminate earlier than the specific termination date as stated in the prospectus. Consult your tax advisor for possible tax consequences associated with this investment. An investment in this unmanaged unit investment trust should be made with an understanding of the risks associated therewith that includes, but is not limited to: Common Stock: An investment in common stocks should be made with an understanding of the various risks of owning common stock, such as an economic recession and the possible deterioration of either the financial condition of the issuers of the equity securities or the general condition of the stock market. Health Care Companies Concentration: This trust is considered to be concentrated in companies in the health care industry which are subject to governmental regulation of their products and services. Companies in this sector face a number of risks including research and development costs, potential to not offer products for several years, and erratic revenue patterns. Long-Term Strategy: The UIT matures in approximately 2 years and, as such, investors should consider their ability to reinvest any proceeds in a subsequent UIT, if available, with a like or differing strategy, at the applicable sales charge. Peroni Method®: The Peroni Method® may not identify stocks that will satisfy the trust’s investment objective. Small and Mid-Size Companies: The trust is considered to be concentrated in securities issued by small and mid-size companies. These stocks are often more volatile and have lower trading volumes than stocks of larger companies. Small and mid-size companies may have limited products or financial resources, management inexperience and less publicly available information. The Morningstar Equity Style Box™: This table provides a graphical representation of the investment style of a trust based on holdings as of the date of deposit which may vary thereafter. The Morningstar Equity Style Box™ placement is based on the Morningstar market capitalization classification (determined relative to other stocks in the same geographic area) of the stocks in the trust's portfolio (vertical axis), and by comparing the growth and value characteristics of the stocks in the trust's portfolio with growth and value factors developed by Morningstar (horizontal axis). Value, blend and growth are types of investment styles. Growth investing generally seeks stocks that offer the potential for greater-than-average earnings growth, and may entail greater risk than value or blend investing. Value investing generally seeks stocks that may be sound investments but are temporarily out of favor in the marketplace, and may entail less risk than growth investing. A blended investment combines the two styles. ©2020 Morningstar, Inc. All Rights Reserved. The information contained herein relating to the Morningstar Equity Style Box™: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.

Securities are available through your financial professional. Not FDIC Insured. Not Bank Guaranteed. May Lose Value. For informational purposes only and not a recommendation to purchase or sell any security.

©2020 Advisors Asset Management Advisors Asset Management, Inc. (AAM) is a SEC registered investment advisor and member FINRA/SIPC.

18925 Base Camp Road | Monument, CO 80132 | www.aamlive.com | CRN: 2020-0609-8362 R Link 6690

Page 4 of 4 FOR MORGAN STANLEY WEALTH MANAGEMENT USE ONLY.

Intelligent Investments. Independent Ideas.